×
About 2,918 results

ALLMedicine™ IgA Nephropathy Center

Research & Reviews  1,101 results

Comparison of clinical, pathological and long-term renal outcomes of children with Heno...
https://doi.org/10.1007/s11255-021-03063-7 10.1007/s00296-016-3425-3 10.1007/s00467-017-3597-4 10.1007/s11695-017-2940-y
International Urology and Nephrology; Torun Bayram M, Heybeli C et. al.

Dec 1st, 2021 - To compare clinical, pathological, and long-term renal outcomes of children with Henoch-Schonlein purpura nephritis (HSPN) and IgA nephropathy (IgAN). The medical records of patients diagnosed as HSPN and IgAN during childhood were evaluated retro...

Use of biologic agents and methotrexate improves renal manifestation and outcome in pat...
https://doi.org/10.1007/s10157-021-02160-2 10.1002/art.1780380213 10.1002/art.27584 10.1053/j.ajkd.2008.12.034 10.1007/s10157-013-0810-z 10.1053/ajkd.2002.31987 10.1159/000093254 10.1136/ard.49.6.363 10.3899/jrheum.111453 10.1097/RHU.0000000000000302 10.1007/s10238-019-00602-6 10.5414/CN109971 10.1080/24725625.2020.1739193 10.2215/CJN.07420716
Clinical and Experimental Nephrology; Sawamura M, Sawa N et. al.

Dec 1st, 2021 - We examined whether advances in treatment strategies from older disease-modifying antirheumatic drugs (DMARDs) to new biologic agents and methotrexate improved renal complications and outcome in patients with rheumatoid arthritis (RA). We reviewed...

Avacopan: First Approval.
https://doi.org/10.1007/s40265-021-01643-6 10.1002/art.37715 10.1056/NEJMoa2023386 10.1371/journal.pone.0164646 10.1681/ASN.2013020143 10.1056/NEJMc2104672 10.1002/acr2.11185 10.1681/ASN.2016111179
Drugs Lee A

Nov 27th, 2021 - Avacopan (TAVNEOS™) is a complement 5a receptor (C5aR) antagonist developed by ChemoCentryx for the treatment of autoimmune diseases including anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. The therapeutic effects of avacop...

Identification of miRNA-mRNA network and immune-related gene signatures in IgA nephropa...
https://doi.org/10.1186/s12882-021-02606-5
BMC Nephrology; Wei SY, Guo S et. al.

Nov 27th, 2021 - IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, and its diagnosis depends mainly on renal biopsy. However, there is no specific treatment for IgAN. Moreover, its causes and underlying molecular events requir...

Immunological drivers of IgA nephropathy: Exploring the mucosa-kidney link.
https://doi.org/10.1111/iji.12561
International Journal of Immunogenetics; Selvaskandan H, Barratt J et. al.

Nov 26th, 2021 - IgA nephropathy (IgAN) is the most common pattern of primary glomerular disease reported worldwide. Up to 40% of those with IgAN progress to end-stage kidney disease within 20 years of diagnosis, with no currently available disease-specific treatm...

see more →

Guidelines  2 results

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Evidence-based clinical practice guidelines for IgA nephropathy 2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956709
Clinical and Experimental Nephrology; Yuzawa Y, Yamamoto R et. al.

Apr 21st, 2016 - Evidence-based clinical practice guidelines for IgA nephropathy 2014.|2016|Yuzawa Y,Yamamoto R,Takahashi K,Katafuchi R,Tomita M,|diagnosis,etiology,therapy,

see more →

Clinicaltrials.gov  34 results

The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
https://clinicaltrials.gov/ct2/show/NCT05132621

Nov 24th, 2021 - The study hypothesis: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical manifestations. Its mechanisms are not well understood. It is known that its development is influenced by genetic factors an...

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
https://clinicaltrials.gov/ct2/show/NCT04578834

Nov 17th, 2021 - This trial is a multicenter, randomized, double-blind, placebo controlled parallel group study. The purpose of the study is to evaluate the efficacy and safety of LNP023 compared to placebo on proteinuria reduction and slowing disease progression ...

The Clinical Trial of ADR-001 for IgA Nephropathy
https://clinicaltrials.gov/ct2/show/NCT04342325

Nov 12th, 2021 - The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the efficacy of ADR-001 for IgA Nephropathy patients.

Atrasentan in Patients With IgA Nephropathy
https://clinicaltrials.gov/ct2/show/NCT04573478

Oct 25th, 2021 - Approximately 320 patients with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo daily for 132 weeks. Subjects receive a maximally tolerated and stable dose of a RAS (renin-angiotensin system) inhibitor (such as angio...

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria and Complement-Mediated Renal Disease
https://clinicaltrials.gov/ct2/show/NCT05083364

Oct 19th, 2021 - The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and adult patients with complement-m...

see more →

News  26 results

'Strong Evidence' Oral Steroids Slow IgA Nephropathy Progression
https://www.medscape.com/viewarticle/962639

Nov 10th, 2021 - Daily treatment of patients with IgA nephropathy with an oral glucocorticoid, methylprednisolone, led to significant reductions in the rate of kidney failure and a composite tally of adverse incident renal outcomes in a multicenter, randomized tri...

Complement Inhibitor Shows Early Promise in IgA Nephropathy
https://www.medscape.com/viewarticle/952739

Jun 9th, 2021 - A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the first targeted therapy for the treatment of IgA nephrop...

FDA Extends Review Period for Narsoplimab for HSCT-TMA
https://www.onclive.com/view/fda-extends-review-period-for-narsoplimab-for-hsct-tma

May 21st, 2021 - The FDA has announced that it will need more time to review the biologics license application (BLA) for narsoplimab as a potential therapeutic option in patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-T...

New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy
https://www.medscape.com/viewarticle/949579

Apr 20th, 2021 - Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) was safe and effective for slowing progression of chronic kidney disease (CKD) and the development of end-stage renal disease for patients with immunoglobu...

Severe renal arteriosclerosis may indicate cardiovascular risk in lupus nephritis
https://www.mdedge.com/rheumatology/article/234917/lupus-connective-tissue-diseases/severe-renal-arteriosclerosis-may
Heidi Splete

Jan 22nd, 2021 - Severe renal arteriosclerosis was associated with a ninefold increased risk of atherosclerotic cardiovascular disease in patients with lupus nephritis, based on data from an observational study of 189 individuals. Mohammed Haneefa Nizamudeen/Getty.

see more →

Patient Education  4 results see all →